Cannabinoids in multiple sclerosis: A neurophysiological analysis.
Administration, Oral
Adult
Cannabidiol
/ administration & dosage
Dronabinol
/ administration & dosage
Drug Combinations
Female
Humans
Male
Middle Aged
Multiple Sclerosis, Chronic Progressive
/ complications
Muscle Spasticity
/ drug therapy
Muscle, Skeletal
/ drug effects
Pain
/ drug therapy
Pilot Projects
Treatment Outcome
cannabinoids
multiple sclerosis I spasticity I pain I H/M ratio I cutaneous silent period
Journal
Acta neurologica Scandinavica
ISSN: 1600-0404
Titre abrégé: Acta Neurol Scand
Pays: Denmark
ID NLM: 0370336
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
29
04
2020
revised:
20
06
2020
accepted:
29
06
2020
pubmed:
8
7
2020
medline:
9
2
2021
entrez:
8
7
2020
Statut:
ppublish
Résumé
To investigate the action of cannabinoids on spasticity and pain in secondary progressive multiple sclerosis, by means of neurophysiological indexes. We assessed 15 patients with progressive MS (11 females) using clinical scales for spasticity and pain, as well as neurophysiological variables (H/M ratio, cutaneous silent period or CSP). Testing occurred before (T0) and during (T1) a standard treatment with an oral spray containing delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Neurophysiological measures at T0 were compared with those of 14 healthy controls of similar age and sex (HC). We then compared the patient results at the two time points (T1 vs T0). At T0, neurophysiological variables did not differ significantly between patients and controls. At T1, spasticity and pain scores improved, as detected by the Modified Ashworth Scale or MAS (P = .001), 9-Hole Peg Test or 9HPT (P = .018), numeric rating scale for spasticity or NRS (P = .001), and visual analogue scale for pain or VAS (P = .005). At the same time, the CSP was significantly prolonged (P = .001). The THC-CBD spray improved spasticity and pain in secondary progressive MS patients. The spray prolonged CSP duration, which appears a promising tool for assessing and monitoring the analgesic effects of THC-CBD in MS.
Substances chimiques
Drug Combinations
0
Cannabidiol
19GBJ60SN5
Dronabinol
7J8897W37S
nabiximols
K4H93P747O
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
333-338Subventions
Organisme : Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy
Informations de copyright
© 2020 John Wiley & Sons A/S . Published by John Wiley & Sons Ltd.
Références
Patti F, Messina S, Solaro C, et al. Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. J Neurol Neurosurg Psychiatry. 2016;87(9):944-951.
Howlett AC, Abood ME. CB1 and CB2 receptor pharmacology. Adv Pharmacol. 2017;80:169-206.
Robson P. Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine. Expert Opin Drug Saf. 2011;10(5):675-685.
Starowicz K, Finn DP. Cannabinoids and pain: sites and mechanisms of action. Adv Pharmacol. 2017;80:437-475.
Manzanares J, Julian M, Carrascosa A. Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. Curr Neuropharmacol. 2006;4(3):239-257.
Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65(6):812-819.
D'Amico E, Haase R, Ziemssen T. Review: patient-reported outcomes in multiple sclerosis care. Mult Scler Relat Disord. 2019;33:61-66.
Stokic DS, Yablon SA, Hayes A, Vesovic-Potic V, Olivier J. Dose-response relationship between the H-reflex and continuous intrathecal baclofen administration for management of spasticity. Clin Neurophysiol. 2006;117(6):1283-1289.
Hoving MA, van Raak EPM, Spincemaille GHJJ, Palmans LJ, Becher JG, Vles JSH. Efficacy of intrathecal baclofen therapy in children with intractable spastic cerebral palsy: a randomised controlled trial. Eur J Paediatr Neurol. 2009;13(3):240-246.
Kofler M, Leis AA, Valls-Solé J. Cutaneous silent periods - part 2: update on pathophysiology and clinical utility. Clin Neurophysiol. 2019;130(4):604-615.
Kofler M, Leis AA, Valls-Solé J. Cutaneous silent periods - part 1: update on physiological mechanisms. Clin Neurophysiol. 2019;130(4):588-603.
Comi G, Solari A, Leocani L, et al. Italian consensus on treatment of spasticity in multiple sclerosis. Eur J Neurol. 2020;27(3):445-453.
Karschner EL, Darwin WD, Goodwin RS, Wright S, Huestis MA. Plasma cannabinoid pharmacokinetics following controlled oral Δ 9-tetrahydrocannabinol and oromucosal cannabis extract administration. Clin Chem. 2011;57(1):66-75.
Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther. 1987;67(2):206-207.
Feys P, Lamers I, Francis G, et al. The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis. Mult Scler. 2017;23(5):711-720.
Motl RW, Cohen JA, Benedict R, et al. Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis. Mult Scler. 2017;23(5):704-710.
Farrar JT, Troxel AB, Stott C, Duncombe P, Jensen MP. Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial. Clin Ther. 2008;30(5):974-985.
Heller GZ, Manuguerra M, Chow R. How to analyze the Visual Analogue Scale: myths, truths and clinical relevance. Scand J Pain. 2016;13:67-75.
Burke D, Hallett M, Fuhr P, Pierrot-Deseilligny E. H reflexes from the tibial and median nerves. The International Federation of Clinical Neurophysiology. Electroencephalogr Clin Neurophysiol Suppl. 1999;52:259-262.
Pinelli P, Valle M. Physiopathological study of the muscular reflexes in spastic paresis (on the tests for the measurements of spasticity). Arch Sci Med. 1960;110:77-202.
Angel RW, Hofmann WW. The H reflex in normal, spastic, and rigid subjects: studies. Arch Neurol. 1963;8(6):591-596.
Matthews WB. Ratio of maximum H reflex to maximum M response as a measure of spasticity. J Neurol Neurosurg Psychiatry. 1966;29(3):201-204.
Ørsnes G, Crone C, Krarup C, Petersen N, Nielsen J. The effect of baclofen on the transmission in spinal pathways in spastic multiple sclerosis patients. Clin Neurophysiol. 2000;111(8):1372-1379.
Conte A, Bettolo CM, Onesti E, et al. Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis. Eur J Pain. 2009;13(5):472-477.
Leocani L, Nuara A, Houdayer E, et al. Sativex® and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis. J Neurol. 2015;262(11):2520-2527.
Squintani G, Donato F, Turri M, et al. Cortical and spinal excitability in patients with multiple sclerosis and spasticity after oromucosal cannabinoid spray. J Neurol Sci. 2016;370:263-268.
Sheean G. The pathophysiology of spasticity. Eur J Neurol Suppl. 2002;9(1):3-9.
Kumru H, Stetkarova I, Schindler C, Vidal J, Kofler M. Neurophysiological evidence for muscle tone reduction by intrathecal baclofen at the brainstem level. Clin Neurophysiol. 2011;122(6):1229-1237.
Cheung J, Rancourt A, Di Poce S, et al. Patient-identified factors that influence spasticity in people with stroke and multiple sclerosis receiving botulinum toxin injection treatments. Physiother Can. 2015;67(2):157-166.
Ferraro D, Plantone D, Morselli F, et al. Systematic assessment and characterization of chronic pain in multiple sclerosis patients. Neurol Sci. 2018;39(3):445-453.
Thong ISK, Jensen MP, Miró J, Tan G. The validity of pain intensity measures: What do the NRS, VAS, VRS, and FPS-R measure? Scand J Pain. 2018;18(1):99-107.
Turri M, Teatini F, Donato F, et al. Pain modulation after oromucosal cannabinoid spray (SATIVEX®) in patients with multiple sclerosis: a study with quantitative sensory testing and laser-evoked potentials. Medicines. 2018;5(3):59.
Von Dincklage F, Send K, Hackbarth M, Rehberg B, Baars JH. Comparison of the nociceptive flexion reflex threshold and the bispectral index as monitors of movement responses to noxious stimuli under propofol mono-anaesthesia. Br J Anaesth. 2009;102(2):244-250.
Rossi P, Pierelli F, Parisi L, et al. Effect of painful heterotopic stimulation on the cutaneous silent period in the upper limbs. Clin Neurophysiol. 2003;114(1):1-6.
Kofler M. Influence of transcutaneous electrical nerve stimulation on cutaneous silent periods in humans. Neurosci Lett. 2004;360(1-2):69-72.
Inghilleri M, Conte A, Frasca V, Berardelli A, Manfredi M, Cruccu G. Is the cutaneous silent period an opiate-sensitive nociceptive reflex? Muscle Nerve. 2002;25(5):695-699.
Fionda L, Cambieri C, Ceccanti M, et al. 42. The effects of THC on cutaneous silent period. Clin Neurophysiol. 2016;127:e142.
Pujia F, Coppola G, Anastasio MG, et al. Cutaneous silent period in hand muscles is lengthened by tramadol: evidence for monoaminergic modulation? Neurosci Lett. 2012;528(1):78-82.
Pujia F, Serrao M, Brienza M, et al. Effects of a selective serotonin reuptake inhibitor escitalopram on the cutaneous silent period: a randomized controlled study in healthy volunteers. Neurosci Lett. 2014;566:17-20.
Yang F, Xu Q, Shu B, et al. Activation of cannabinoid CB1 receptor contributes to suppression of spinal nociceptive transmission and inhibition of mechanical hypersensitivity by Aβ-fiber stimulation. Pain. 2016;157(11):2582-2593.
Stokic DS, Kofler M, Stetkarova I, Leis AA. Exteroceptive suppression of voluntary activity in thenar muscles by cutaneous stimulation: How many trials should be averaged? Clin Neurol Neurosurg. 2019;184:105452.